Turning Point Therapeutics, Inc. (TPTX) has a consensus analyst rating of Buy, based on 14 analysts covering the stock. Of those, 8 recommend buying, 6 recommend holding, and 0 recommend selling.
The analyst consensus price target for TPTX is $73.60, representing a -2.5% downside from the current price of $75.49. Price targets range from a low of $73.60 to a high of $73.60.
